Wells Fargo analyst Mohit Bansal raised the firm’s price target on Travere Therapeutics (TVTX) to $35 from $27 and keeps an Overweight rating on the shares to reflect increased confidence in focal segmental glomerulosclerosis approval. IgAN momentum also provides support, but the next critical catalyst and inflection point could be the January 13th PDUFA for FSGS, the firm adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
- Positive Outlook for Travere Therapeutics: Buy Rating Supported by FILSPARI’s Strong Data and Competitive Advantages
- AdCom cancellation ‘clear positive’ for Travere Therapeutics, says Jefferies
- FDA reversing course on adcomm should reassure Travere investors, says BofA
- FDA Drops Advisory Committee for Travere’s FILSPARI Review